A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
Neurofibromatosis Type 1
DRUG: HLX-1502
PN response rate, Response will be determined by a blinded centralized review of volumetric MRI. A partial response (PR) is defined as ≥ 20% decrease in the volume of target PN., 12 months
Duration of response (DOR) and Time to response (TOR), Response will be determined by a blinded centralized review of volumetric MRI., 12 months|Safety and tolerability of HLX-1502, Adverse events (AEs) will be assessed according to toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., 12 months|PN response rate, Response will be determined by a blinded centralized review of volumetric MRI. A partial response (PR) is defined as ≥ 20% decrease in the volume of target PN., 24 months|Pharmacokinetics of HLX-1502, Measured by plasma concentrations, 12 months|Confirmed PN response rate, Confirmed response will be determined by a blinded centralized review of volumetric MRI, 12 and 24 months
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.